Clinical Trial: Phase II Single-Arm Exploratory Study of Glutamine Combined with XELOX Regimen (Oxaliplatin plus Capecitabine), Bevacizumab and Sintilimab as First-Line Therapy for Advanced Colorectal Cancer with KRAS G12D Mutation (China)

China, Aug. 17 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Phase II Single-Arm Exploratory Study of Glutamine Combined with XELOX Regimen (Oxaliplatin plus Capecitabine), Bevacizumab and Sintilimab as First-Line Therapy for Advanced Colorectal Cancer with KRAS G12D Mutation'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130117

Registration Time: 2026/08/14

Type: Interventional study

Primary Sponsor: The Second Affiliated Hospital of Zhejiang University School of Medicine

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=335004

Published by HT Digital Content Services with permission from Health Daily Digest....